Patterns of pharmacotherapy in patients hospitalised for congestive heart failure

被引:19
作者
Bouvy, ML
Heerdink, ER
Leufkens, HGM
Hoes, AW
机构
[1] Utrecht Inst Pharmaceut Sci, Dept Pharmacoepidemiol & Pharmacol, UIPS, NL-3508 TB Utrecht, Netherlands
[2] SIR Inst Pharm Practice Res, Leiden, Netherlands
[3] Univ Utrecht, Ctr Med, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
关键词
ACE-inhibitors; beta-blockers; diuretics; digoxin; antithrombotics; heart failure; medication patterns; persistence of therapy;
D O I
10.1016/S1388-9842(02)00256-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In the 1990s, a number of cardio vascular drugs were evaluated in randomised clinical trials. Treatment guidelines for heart failure were modified to include these evidence-based treatments. Aim: To evaluate the impact of ne v medical treatments for heart failure between 1990 and 1998. Methods and results: A retrospective cohort study of 2764 patients with a first hospital admission for heart failure between 1990 and 1998. The percentage of patients treated with different cardiovascular drugs after hospitalisation A,as calculated and compared over time. Use of loop diuretics remained steady approximately 80% digoxin decreased from 57.6 to 42.7%, angiotensin converting enzyme (ACE) inhibitors showed a slight increase from 49.8 to 54.8%, beta-blockers almost tripled from 11.3 to 28.7%. low dose prophylactic acetylsalicylic acid quadrupled from 9.9 to 39.9%. Kaplan-Meier survival estimates showed highest continuation rates of drug treatment for antithrombotics and diuretics, intermediate for digoxin and ACE inhibitors and low for beta-blockers. More than a quarter of the users discontinued beta-blockers in the first year after hospitalisation. Conclusions: We observed an increase in the prescribing of several important drug classes. reflecting changes in treatment guidelines during the study period. However. our findings show that not all patients were receiving optimal treatment. More research into the reasons for this is warranted. (C) 2003 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 33 条
[1]   Efficacy and safety of calcium channel blockers in heart failure: Focus on recent trials with second-generation dihydropyridines [J].
de Vries, RJM ;
van Veldhuisen, DJ ;
Dunselman, PHJM .
AMERICAN HEART JOURNAL, 2000, 139 (02) :185-194
[2]   Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction:: The EPICAL study [J].
Echemann, M ;
Zannad, F ;
Briançon, S ;
Juillière, Y ;
Mertès, PM ;
Virion, JM ;
Villemot, JP .
AMERICAN HEART JOURNAL, 2000, 139 (04) :624-631
[3]   Risk factors for mortality in users of ibopamine [J].
Feenstra, J ;
in't Veld, BA ;
van der Linden, PD ;
Grobbee, DE ;
Stricker, BHC .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) :71-77
[4]   Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure [J].
Hampton, JR ;
vanVeldhuisen, DJ ;
Kleber, FX ;
Cowley, AJ ;
Ardia, A ;
Block, P ;
Cortina, A ;
Cserhalmi, L ;
Follath, F ;
Jensen, G ;
Kayanakis, J ;
Lie, KI ;
Mancia, G ;
Skene, AM .
LANCET, 1997, 349 (9057) :971-977
[5]  
HEERDINK ER, 1995, THESIS UTRECHT U UTR
[6]   PHARMACO-MORBIDITY LINKAGE - A FEASIBILITY STUDY COMPARING MORBIDITY IN 2 PHARMACY BASED EXPOSURE COHORTS [J].
HERINGS, RMC ;
BAKKER, A ;
STRICKER, BHC ;
NAP, G .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1992, 46 (02) :136-140
[7]  
Hjalmarson Å, 1999, LANCET, V353, P2001
[8]   European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF) [J].
Hobbs, FDR ;
Jones, MI ;
Allan, TF ;
Wilson, S ;
Tobias, R .
EUROPEAN HEART JOURNAL, 2000, 21 (22) :1877-1887
[9]  
Hoes A. W., 1998, European Heart Journal, V19, pL2
[10]  
Kennedy Harold L., 2001, American Journal of Medicine, V110, p2S